Do analysts rate MYNZ or ELUT?

Elutia has a consensus target price of $6.00, suggesting a potential upside of 545.16%. Given Elutia's stronger consensus rating and higher probable upside, analysts plainly believe Elutia is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Elutia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, MYNZ or ELUT?

Elutia has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $659.94K 14.83 -$21.65M -$65.60 N/A Elutia $12.29M 3.24 $53.38M $0.86 1.08

Is MYNZ or ELUT more profitable?

Elutia has a net margin of 312.09% compared to Mainz Biomed's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Elutia 312.09% N/A -53.97%

Do analysts recommend APLM or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation & earnings, APLM or MYNZ?

Apollomics has higher revenue and earnings than Mainz Biomed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 4.81 -$10.94M N/A N/A Mainz Biomed $659.94K 14.83 -$21.65M -$65.60 N/A

Is APLM or MYNZ more profitable?

Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Mainz Biomed N/A N/A N/A

Do analysts rate MYNZ or SCYX?

SCYNEXIS has a consensus target price of $24.00, indicating a potential upside of 543.43%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, MYNZ or SCYX?

SCYNEXIS has higher revenue and earnings than Mainz Biomed. SCYNEXIS is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $659.94K 14.83 -$21.65M -$65.60 N/A SCYNEXIS $20.60M 1.80 -$8.61M -$3.84 N/A

Do analysts rate MYNZ or GRCE?

Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 157.51%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Grace Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MYNZ or GRCE more profitable?

Mainz Biomed's return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Grace Therapeutics N/A -14.45% -13.58%

Does the media favor MYNZ or GRCE?

In the previous week, Grace Therapeutics had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Grace Therapeutics and 1 mentions for Mainz Biomed. Grace Therapeutics' average media sentiment score of 0.95 beat Mainz Biomed's score of 0.75 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RNXT or MYNZ?

RenovoRx currently has a consensus target price of $8.50, suggesting a potential upside of 882.32%. Given RenovoRx's stronger consensus rating and higher probable upside, equities analysts clearly believe RenovoRx is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings and valuation, RNXT or MYNZ?

RenovoRx has higher revenue and earnings than Mainz Biomed. RenovoRx is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RenovoRx $1.12M 34.81 -$11.17M -$0.33 N/A Mainz Biomed $659.94K 14.83 -$21.65M -$65.60 N/A

Is RNXT or MYNZ more profitable?

Mainz Biomed has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Mainz Biomed's return on equity of 0.00% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -823.98% -135.03% -101.92% Mainz Biomed N/A N/A N/A

Mainz Biomed (MYNZ) Competitors

$1.08 -0.03 (-2.70%)

As of 07/24/2026

Compare

MYNZ vs. ELUT, APLM, SCYX, GRCE, and RNXT

Should you buy Mainz Biomed stock or one of its competitors? MarketBeat compares Mainz Biomed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mainz Biomed include Elutia (ELUT), Apollomics (APLM), SCYNEXIS (SCYX), Grace Therapeutics (GRCE), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry.

How does Mainz Biomed compare to Elutia?

Mainz Biomed (NASDAQ:MYNZ) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Elutia has a consensus target price of $6.00, suggesting a potential upside of 545.16%. Given Elutia's stronger consensus rating and higher probable upside, analysts plainly believe Elutia is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Elutia has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	14.83	-$21.65M	-$65.60	N/A
Elutia	$12.29M	3.24	$53.38M	$0.86	1.08

Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Elutia has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Elutia has a net margin of 312.09% compared to Mainz Biomed's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Elutia	312.09%	N/A	-53.97%

In the previous week, Mainz Biomed and Mainz Biomed both had 1 articles in the media. Elutia's average media sentiment score of 1.87 beat Mainz Biomed's score of 0.75 indicating that Elutia is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Positive
Elutia	Very Positive

74.0% of Elutia shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 17.8% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Elutia beats Mainz Biomed on 11 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to Apollomics?

Apollomics (NASDAQ:APLM) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Apollomics has higher revenue and earnings than Mainz Biomed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	4.81	-$10.94M	N/A	N/A
Mainz Biomed	$659.94K	14.83	-$21.65M	-$65.60	N/A

19.1% of Apollomics shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Apollomics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Mainz Biomed	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 1.87 beat Mainz Biomed's score of 0.75 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Very Positive
Mainz Biomed	Positive

Summary

Apollomics beats Mainz Biomed on 5 of the 8 factors compared between the two stocks.

How does Mainz Biomed compare to SCYNEXIS?

Mainz Biomed (NASDAQ:MYNZ) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

In the previous week, Mainz Biomed and Mainz Biomed both had 1 articles in the media. SCYNEXIS's average media sentiment score of 1.87 beat Mainz Biomed's score of 0.75 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Positive
SCYNEXIS	Very Positive

SCYNEXIS has a consensus target price of $24.00, indicating a potential upside of 543.43%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

54.4% of SCYNEXIS shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by company insiders. Comparatively, 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SCYNEXIS has higher revenue and earnings than Mainz Biomed. SCYNEXIS is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	14.83	-$21.65M	-$65.60	N/A
SCYNEXIS	$20.60M	1.80	-$8.61M	-$3.84	N/A

Mainz Biomed has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Mainz Biomed's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
SCYNEXIS	-41.79%	-57.16%	-39.48%

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Summary

SCYNEXIS beats Mainz Biomed on 9 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to Grace Therapeutics?

Mainz Biomed (NASDAQ:MYNZ) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

6.1% of Grace Therapeutics shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 11.1% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Grace Therapeutics has lower revenue, but higher earnings than Mainz Biomed. Grace Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	14.83	-$21.65M	-$65.60	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 157.51%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mainz Biomed's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Grace Therapeutics	N/A	-14.45%	-13.58%

In the previous week, Grace Therapeutics had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Grace Therapeutics and 1 mentions for Mainz Biomed. Grace Therapeutics' average media sentiment score of 0.95 beat Mainz Biomed's score of 0.75 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mainz Biomed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mainz Biomed has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Summary

Grace Therapeutics beats Mainz Biomed on 9 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Mainz Biomed has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Mainz Biomed's return on equity of 0.00% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Mainz Biomed	N/A	N/A	N/A

In the previous week, RenovoRx and RenovoRx both had 1 articles in the media. RenovoRx's average media sentiment score of 0.94 beat Mainz Biomed's score of 0.75 indicating that RenovoRx is being referred to more favorably in the media.

Company	Overall Sentiment
RenovoRx	Positive
Mainz Biomed	Positive

RenovoRx currently has a consensus target price of $8.50, suggesting a potential upside of 882.32%. Given RenovoRx's stronger consensus rating and higher probable upside, equities analysts clearly believe RenovoRx is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

RenovoRx has higher revenue and earnings than Mainz Biomed. RenovoRx is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	34.81	-$11.17M	-$0.33	N/A
Mainz Biomed	$659.94K	14.83	-$21.65M	-$65.60	N/A

3.1% of RenovoRx shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

RenovoRx has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Summary

RenovoRx beats Mainz Biomed on 11 of the 16 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYNZ vs. The Competition

Export

Metric	Mainz Biomed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.79M	$3.67B	$6.93B	$12.20B
Dividend Yield	N/A	2.19%	2.67%	9.41%
P/E Ratio	-0.02	21.29	27.14	23.62
Price / Sales	14.83	297.80	523.81	89.60
Price / Cash	N/A	153.89	49.81	58.78
Price / Book	0.41	7.88	10.28	6.01
Net Income	-$21.65M	$23.86M	$3.60B	$331.99M
7 Day Performance	-12.20%	-3.82%	-1.27%	-0.63%
1 Month Performance	-26.53%	-2.61%	-0.37%	-2.00%
1 Year Performance	-47.06%	32.79%	18.30%	13.62%

Mainz Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYNZ Mainz Biomed	0.4513 of 5 stars	$1.08 -2.7%	N/A	-44.2%	$9.79M	$659.94K	N/A	30
ELUT Elutia	3.8243 of 5 stars	$0.95 +2.1%	$6.00 +531.6%	-51.1%	$40.65M	$12.46M	1.10	180	Positive News Analyst Downgrade Gap Up
APLM Apollomics	0.8238 of 5 stars	$18.44 -2.3%	N/A	+202.2%	$40.56M	$8.50M	N/A	45	Positive News Gap Down
SCYX SCYNEXIS	3.4963 of 5 stars	$4.03 +3.7%	$24.00 +494.9%	-36.8%	$40.06M	$20.60M	N/A	60	Positive News
GRCE Grace Therapeutics	2.0892 of 5 stars	$2.45 +0.8%	$6.00 +144.9%	-27.2%	$39.86M	N/A	N/A	N/A	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYNZ) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mainz Biomed (MYNZ) Competitors

MYNZ vs. ELUT, APLM, SCYX, GRCE, and RNXT

How does Mainz Biomed compare to Elutia?

Summary

How does Mainz Biomed compare to Apollomics?

Summary

How does Mainz Biomed compare to SCYNEXIS?

Summary

How does Mainz Biomed compare to Grace Therapeutics?

Summary

How does Mainz Biomed compare to RenovoRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mainz Biomed (MYNZ) Competitors

MYNZ vs. ELUT, APLM, SCYX, GRCE, and RNXT

How does Mainz Biomed compare to Elutia?

Do analysts rate MYNZ or ELUT?

Which has stronger valuation & earnings, MYNZ or ELUT?

Which has more risk & volatility, MYNZ or ELUT?

Is MYNZ or ELUT more profitable?

Does the media favor MYNZ or ELUT?

Do insiders & institutionals hold more shares of MYNZ or ELUT?

Summary

How does Mainz Biomed compare to Apollomics?

Which has higher valuation & earnings, APLM or MYNZ?

Do institutionals and insiders believe in APLM or MYNZ?

Which has more volatility and risk, APLM or MYNZ?

Is APLM or MYNZ more profitable?

Do analysts recommend APLM or MYNZ?

Does the media refer more to APLM or MYNZ?

Summary

How does Mainz Biomed compare to SCYNEXIS?

Does the media favor MYNZ or SCYX?

Do analysts rate MYNZ or SCYX?

Do insiders and institutionals have more ownership in MYNZ or SCYX?

Which has higher valuation & earnings, MYNZ or SCYX?

Is MYNZ or SCYX more profitable?

Which has more risk and volatility, MYNZ or SCYX?

Summary

How does Mainz Biomed compare to Grace Therapeutics?

Do insiders & institutionals have more ownership in MYNZ or GRCE?

Which has preferable earnings and valuation, MYNZ or GRCE?

Do analysts rate MYNZ or GRCE?

Is MYNZ or GRCE more profitable?

Does the media favor MYNZ or GRCE?

Which has more risk & volatility, MYNZ or GRCE?

Summary

How does Mainz Biomed compare to RenovoRx?

Is RNXT or MYNZ more profitable?

Does the media refer more to RNXT or MYNZ?

Do analysts prefer RNXT or MYNZ?

Which has better earnings and valuation, RNXT or MYNZ?

Do institutionals and insiders have more ownership in RNXT or MYNZ?

Which has more volatility and risk, RNXT or MYNZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools